SPAC Northern Lights Amends Unit Purchase Agreement To Extend Outside Date
Northern Lights Acquisition Corp.
Goldman Sachs Maintains Neutral on RH, Lowers Price Target to $224
Goldman Sachs analyst Kate McShane maintains RH (NYSE:RH) with a Neutral and lowers the price target from $262 to $224.
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours:
JP Morgan Maintains Overweight on Comerica, Lowers Price Target to $97
JP Morgan analyst Steven Alexopoulos maintains Comerica (NYSE:CMA) with a Overweight and lowers the price target from $108 to $97.
JP Morgan Maintains Underweight on BankUnited, Lowers Price Target to $38
JP Morgan analyst Steven Alexopoulos maintains BankUnited (NYSE:BKU) with a Underweight and lowers the price target from $43 to $38.
Blueprint Medicines Received FDA Orphan Drug Designation for Treatment of Mastocytosis
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=890922
Wells Fargo Maintains Overweight on Kilroy Realty, Lowers Price Target to $60
Wells Fargo analyst Blaine Heck maintains Kilroy Realty (NYSE:KRC) with a Overweight and lowers the price target from $85 to $60.
Wells Fargo Maintains Equal-Weight on Hudson Pacific Properties, Lowers Price Target to $15
Wells Fargo analyst Blaine Heck maintains Hudson Pacific Properties (NYSE:HPP) with a Equal-Weight and lowers the price target from $30 to $15.